scholarly journals Review of: "Is delay to radical cystectomy following BCG failure oncologically safe?"

Qeios ◽  
2021 ◽  
Author(s):  
Roberto Carando
Keyword(s):  
Radical Cystectomy ◽  
Bcg Failure

753 Oncological outcome of radical cystectomy for BCG failure compared to primary invasive disease

2013 ◽  
Vol 12 (1) ◽  
pp. e753-e754
Author(s):  
A. Masson-Lecomte ◽  
D. Vordos ◽  
R. Yiou ◽  
Y. Allory ◽  
C.C. Abbou ◽  
...  
Keyword(s):  
Radical Cystectomy ◽  
Oncological Outcome ◽  
Invasive Disease ◽  
Bcg Failure

scholarly journals Emerging intravesical therapies for the management of bacillus Calmette–Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward

2020 ◽  
Vol 14 (6) ◽  
Author(s):  
Ali Cyrus Chehroudi ◽  
Peter C. Black
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Radical Cystectomy ◽  
Clinical Trial Design ◽  
Standard Of Care ◽  
Invasive Bladder Cancer ◽  
Intravesical Therapy ◽  
Muscle Invasive Bladder Cancer ◽  
Bcg Failure ◽  
Muscle Invasive

Management of patients with cacillus Calmette–Guérin (BCG)-unresponsive, high-risk, non-muscle-invasive bladder cancer (NMIBC) presents a formidable clinical challenge that requires urologists to weigh the competing risks of progression during further intravesical therapy vs. the morbidity of radical cystectomy. The prognosis of high-risk NMIBC recurring after BCG depends on the adequacy of prior BCG, the timing of recurrence, and tumor histology. The standard of care is currently radical cystectomy, as effective salvage intravesical therapy has not been established. The development of bladder-sparing treatments has been hampered to date by inconsistent definitions of BCG failure and difficulties in identifying appropriate control treatments in clinical trials. Despite these limitations, the spectrum of salvage therapy is expanding to include enhanced intravesical chemo-, gene, and immuno-therapies. In this review, we provide an overview of these emerging agents in the context of our current understanding of BCG failure and the unique considerations for clinical trial design in this disease state.

MP26-11 THE TIMING OF RADICAL CYSTECTOMY FOR BCG FAILURE: COMPARISON OF OUTCOMES AND RISK FACTORS FOR PROGNOSIS

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Christopher Haas ◽  
LaMont Barlow ◽  
G. Joel DeCastro ◽  
James McKiernan
Keyword(s):  
Risk Factors ◽  
Radical Cystectomy ◽  
Bcg Failure

Radical cystectomy for BCG failure: has the timing improved in recent years?

2010 ◽  
Vol 108 (2) ◽  
pp. 182-185 ◽  
Author(s):  
Mark S. Soloway ◽  
David Hepps ◽  
Devendar Katkoori ◽  
Rajinikanth Ayyathurai ◽  
Murugesan Manoharan
Keyword(s):  
Radical Cystectomy ◽  
Bcg Failure

scholarly journals The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Andres F. Correa ◽  
Katherine Theisen ◽  
Matthew Ferroni ◽  
Jodi K. Maranchie ◽  
Ronald Hrebinko ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Disease Recurrence ◽  
Invasive Bladder Cancer ◽  
Intravesical Therapy ◽  
Refractory Disease ◽  
Pathological Stage ◽  
Safe Alternative ◽  
Bcg Failure ◽  
Nonmuscle Invasive Bladder Cancer

Background. Thirty to forty percent of patients with high grade nonmuscle invasive bladder cancer (NMIBC) fail to respond to intravesical therapy with bacillus Calmette-Guerin (BCG). Interferon-α2B plus BCG has been shown to be effective in a subset of patients with NMIBC BCG refractory disease. Here we present a contemporary series on the effectiveness and safety of intravesical BCG plus interferon-α2B therapy in patients with BCG refractory NMIBC.Methods. From January of 2005 to April of 2014 we retrospectively found 44 patients who underwent induction with combination IFN/BCG for the management of BCG refractory NMIBC. A chart review was performed to assess initial pathological stage/grade, pathological stage/grade at the time of induction, time to IFN/BCG failure, pathological stage/grade at failure, postfailure therapy, and current disease state.Results. Of the 44 patients who met criteria for the analysis. High risk disease was found in 88.6% of patients at induction. The 12-month and 24-month recurrence-free survival were 38.6% and 18.2%, respectively. 25 (56.8%) ultimately had disease recurrence. Radical cystectomy was performed in 16 (36.4%) patients.Conclusion. Combination BCG plus interferon-α2B remains a reasonably safe alternative treatment for select patients with BCG refractory disease prior to proceeding to radical cystectomy.

1621 ONCOLOGICAL OUTCOME OF RADICAL CYSTECTOMY FOR BCG FAILURE COMPARED TO PRIMARY INVASIVE DISEASE

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Alexandra Masson-Lecomte ◽  
Dimitri Vordos ◽  
René Yiou ◽  
Yves Allory ◽  
Claude Abbou ◽  
...  
Keyword(s):  
Radical Cystectomy ◽  
Oncological Outcome ◽  
Invasive Disease ◽  
Bcg Failure

573: Radical Cystectomy in Hispanic Patients: An Outcome Analysis

2007 ◽  
Vol 177 (4S) ◽  
pp. 191-191
Author(s):  
Murugesan Manoharan ◽  
Srinivas Samavedi ◽  
Rajinikanth Ayyathurai ◽  
Sachin Vyas ◽  
Mark S. Soloway
Keyword(s):  
Radical Cystectomy ◽  
Outcome Analysis ◽  
Hispanic Patients
Sign in / Sign up

Export Citation Format

Share Document